胃癌新辅助放化疗诱导的淋巴细胞减少与脾脏剂量学及生存结局的关联
本研究纳入2013年6月至2021年12月两家主要中心接受新辅助放化疗(nCRT)或新辅助化疗(nChT)的295例胃癌患者,其中220例为训练队列、75例为外部验证队列。4级及以上淋巴细胞减少在nCRT组比nChT组更常见(训练队列49.5% vs 0,P<0.001;外部验证队列25.0% vs 0,P=0.001),且与更差的无进展生存(PFS)相关(P=0.043)。将脾脏V20限制在<84.5%可使4级及以上淋巴细胞减少发生率降低35.7%。
要点
- 4级及以上淋巴细胞减少在nCRT组比nChT组更常见(训练队列49.5% vs 0,P<0.001)。
- 年龄≥60岁、较低的治疗前绝对淋巴细胞计数、较高的脾脏体积(SPV)和较高的V20是nCRT患者4级及以上淋巴细胞减少的显著危险因素。
- 将脾脏V20限制在<84.5%可使4级及以上淋巴细胞减少发生率降低35.7%。
核心结论
- nCRT期间4级及以上淋巴细胞减少比nChT更常见,且与胃癌患者更差的PFS相关。
- 将脾脏V20限制在<84.5%可能通过保护淋巴细胞间接改善结局。
研究设计与样本
- 研究纳入2013年6月至2021年12月两家主要中心接受nCRT和nChT的295例患者,其中220例为训练队列、75例为外部验证队列。
主要发现
- 4级及以上淋巴细胞减少在nCRT组比nChT组更常见(训练队列49.5% vs 0,P<0.001;外部验证队列25.0% vs 0,P=0.001)。
- 年龄≥60岁(P=0.006)、较低的治疗前绝对淋巴细胞计数(P=0.001)、较高的脾脏体积(SPV)(P=0.001)和较高的V20(P=0.003)是nCRT患者4级及以上淋巴细胞减少的显著危险因素。
- 发生4级及以上淋巴细胞减少的患者PFS显著更差(P=0.043),与OS呈负相关趋势(P=0.07)。
- 将V20限制在<84.5%可使4级及以上淋巴细胞减少发生率降低35.7%。
- 多变量模型在训练队列和外部验证队列的预测效能分别为0.880和0.737。
关键数值与推荐
- 脾脏V20阈值为<84.5%,可使4级及以上淋巴细胞减少发生率降低35.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies concentrate on spleen dosimetry of radiotherapy for gastric cancer (GC). Although there is no consensus on the spleen dose-volume threshold for lymphopenia, several studies indicated that the higher the spleen dose, the higher the risk of lymphopenia. This study aimed to identify the appropriate spleen dosimetric parameters for predicting grade 4 + lymphopenia in patients with locally advanced GC. MATERIAL AND METHODS: A total of 295 patients treated with nCRT and nChT from June 2013 to December 2021 at two major centers were included, of whom 220 were assigned to the training cohort and 75 to the external validation cohort. RESULTS: Grade 4 + lymphopenia was more common in the nCRT than in the nChT group (49.5% vs. 0, P < 0.001 in the training cohort; 25.0% vs. 0, P = 0.001 in the external validation cohort). Age ≥ 60 years (P = 0.006), lower pretreatment absolute lymphocyte count (P = 0.001), higher spleen volume (SPV) (P = 0.001), and higher V20 (P = 0.003) were significant risk factors of grade 4 + lymphopenia for patients treated with nCRT. Patients with grade 4 + lymphopenia had significantly worse PFS (P = 0.043) and showed a negative correlation trend with OS (P = 0.07). Limiting V20 to < 84.5% could decrease the incidence of grade 4 + lymphopenia by 35.7%. The predictive effectiveness of the multivariable model in the training and external validation cohorts was 0.880 and 0.737, respectively. CONCLUSION: Grade 4 + lymphopenia during nCRT was more common than nChT, and was associated with a worse PFS in GC patients. Constraining the spleen V20 to < 84.5% may indirectly improve outcomes through lymphocyte preservation.
引用
- Wang JJ, Shao H, Yan J, et al. Neoadjuvant chemoradiotherapy induced lymphopenia in gastric cancer and associations with spleen dosimetry and survival outcomes. Clin Transl Radiat Oncol. 2023. PMID: 37008513. doi:10.1016/j.ctro.2023.100617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。